ProMis Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto
Ontario
M4S 3E2
United States
Website: http://promisneurosciences.com/
201 articles with ProMis Neurosciences, Inc.
-
The annual Alzheimer’s Association International Conference (AAIC) is running from July 31-August 4 at the San Diego Convention Center and online. Here are some of the highlights presented so far.
-
ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
8/2/2022
ProMIS Neurosciences Inc. announced details of its poster presentation at the annual Alzheimer’s Association International Conference being held from July 31-August 4, 2022 at the San Diego Convention Center, San Diego California and online.
-
Promis Announces Reverse Share Split to Meet NASDAQ Listing Criteria
6/27/2022
ProMIS Neurosciences Inc. announced that, to meet the criteria to list its common shares on the Nasdaq Capital Market, the Board of Directors has approved a 1-for-60 reverse share split, of the Company's issued and outstanding common shares.
-
ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application
6/22/2022
ProMIS Neurosciences Inc. today announced that it has filed a registration statement on Form 10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC").
-
ProMIS Neurosciences Announces Debt Amendment and Conversion
6/22/2022
ProMIS Neurosciences Inc. is pleased to announce that it has entered into debenture amendments with seven (7) creditors to settle an aggregate of US$7,000,000 Series 1 Preferred Shares ("Series 1 Shares") of the Company at US$0.10 per share.
-
ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares
6/22/2022
ProMIS Neurosciences Inc. today announced that it has amended its articles to authorize the issuance of 70,000,000 Series 1 Preferred Shares.
-
ProMIS Neurosciences presents at the 2022 Neuro4D International Conference
5/17/2022
ProMIS Neurosciences, Inc. announced its participation at the Neuro4D International Conference, held at the Atrium Hotel, Mainz, Germany, May 16-17th.
-
ProMIS Neurosciences Announces First Quarter 2022 Results
5/13/2022
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2021.
-
ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
5/13/2022
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”) , is pleased to announce the Annual and Special Meeting of Shareholders (the “Meeting”) of ProMIS was held online by virtual web-cast meeting, on Thursday, May 12, 2022 at 9:00 a.m. (Pacific time).
-
ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
4/28/2022
ProMIS Neurosciences, Inc. announced new milestones in potential therapeutic approaches for ALS.
-
ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer
4/19/2022
ProMIS Neurosciences, Inc. announced that it has appointed Larry Altstiel M.D. Ph.D., as Chief Medical Officer.
-
Following the decision to limit the coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, the Alzheimer’s community is now waiting for other companies to deliver new therapies.
-
ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting
4/7/2022
ProMIS Neurosciences, Inc. announced today that it has presented at the American Academy of Neurology (AAN) Annual Meeting held at the Washington State Convention Center in Seattle, April 2-7, 2022.
-
ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
4/7/2022
ProMIS Neurosciences Inc., is pleased to announce it has mailed the Notice of Notice-and-Access to shareholders of record of the Corporation as of April 01, 2022, in connection with the Annual General and Special Meeting of the Shareholders of the Corporation to be held Thursday, May 12, 2022, at 9:00 a.m.
-
The American Academy of Neurology Annual Meeting (AAN) was held virtually and in-person in Seattle from April 2-7. Here’s a look at some of the highlights.
-
ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
3/24/2022
ProMIS Neurosciences, Inc. announced today that it will be presenting at the upcoming 10th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March 28-30, 2022.
-
ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
3/22/2022
ProMIS Neurosciences, Inc. announced in vivo results of its experimental Alzheimer’s vaccine presented at the AD/PDTM International Conference held in Barcelona Spain, March 15-20, 2022.
-
Esai, Biogen, Diadem and ProMis all presented their findings on biomarker research at this year's International Conference on Alzheimer's and Parkinson's Diseases.
-
ProMIS Neurosciences Announces Fiscal Year 2021 Results
3/17/2022
ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, announced its operational and financial results for the fiscal year ended December 31, 2021.
-
ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
3/10/2022
ProMIS Neurosciences, Inc. announced that it will be presenting at the upcoming AD/PDTM International Conference, to be held in Barcelona Spain, March 15-20, 2022.